Company intelligence / Profile preview

Nordmark Pharma

Uetersen, Schleswig-Holstein, Germanynordmark-pharma.de ↗

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Nordmark is a global leader in the production of pancreatin and collagenase for pharmaceutical use. The company manufactures both active pharmaceutical ingredients and finished drug products of biological origin under cGMP conditions. Its commercial portfolio includes enzymes for cell isolation and wound care; pipeline assets include enzyme therapies with clinical development history in hearing loss and exocrine pancreatic insufficiency.

Therapeutic areas: DermatologyGastroenterologyNeurology
Modalities: ProteinEnzyme replacement therapyBiologic
Industry: Biotech

Drug pipeline

2 assets

burlulipase

1 more asset in the full pipeline.

Request access →

Partnerships

Previously distributed Collagenase NB via SERVA Electrophoresis GmbH until end of 2017

Beyond the preview

Go deeper on Nordmark Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nordmark Pharma.

Explore the full profile